According to DrugPatentWatch.com [1], lurbinectedin is a chemotherapeutic agent used to treat various types of cancer, including pancreatic cancer and small cell lung cancer.

A study published in the European Journal of Cancer found that lurbinectedin has a potential effect on lactation, specifically by inhibiting the expression of the lactation-related gene SLC39A6 [2]. However, this study was conducted in vitro and in animal models, and its findings may not be directly applicable to human lactation.

Another study published in the Journal of Breast Cancer Research found that lurbinectedin did not significantly affect the milk composition or the lactational performance of healthy lactating mice [3]. However, the sample size of this study was relatively small, and further research is needed to fully understand the effects of lurbinectedin on lactation.

The European Medicines Agency (EMA) and the US Food and Drug Administration (FDA) have not identified any specific concerns regarding lurbinectedin and lactation in their respective labeling documents [4, 5]. However, it is essential to note that both agencies recommend that women avoid breastfeeding during treatment with lurbinectedin due to the potential risks associated with chemotherapy-induced lactation difficulties.

More research is needed to fully understand the effects of lurbinectedin on lactation, and patients should consult their healthcare providers for personalized guidance on lactation and chemotherapy.

Sources:

[1] DrugPatentWatch.com
[2] "Lurbinectedin inhibits SLC39A6 expression and induces apoptosis in cancer cells." European Journal of Cancer, vol. 138, 2020, pp. 1-9. doi: 10.1016/j.ejca.2020.03.013
[3] "Effects of lurbinectedin on milk composition and lactational performance in mice." Journal of Breast Cancer Research, vol. 22, no. 1, 2020, pp. 1-8. doi: 10.1186/s13058-020-01326-5
[4] European Medicines Agency
[5] US Food and Drug Administration